navan
/
Daily-Dose
mirror of https://github.com/navanchauhan/Daily-Dose.git
1
0
Fork 0
Code Issues Projects Releases Wiki Activity

Added daily report

This commit is contained in:
Navan Chauhan 2022-11-12 12:55:49 +00:00
parent 36b09a91fe
commit 654f8181f4
3 changed files with 571 additions and 2 deletions
Show Stats Download Patch File Download Diff File Expand all files Collapse all files

186
archive-covid-19/12 November, 2022.html Normal file
View File

@ -0,0 +1,186 @@
<!DOCTYPE html>
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
<meta charset="utf-8"/>
<meta content="pandoc" name="generator"/>
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
<title>12 November, 2022</title>
<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
</style>
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-preprints">From Preprints</a></li>
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
<li><a href="#from-pubmed">From PubMed</a></li>
<li><a href="#from-patent-search">From Patent Search</a></li>
</ul>
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
<ul>
<li><strong>Pandemic panic? Results of a 6-month longitudinal study on fear of COVID-19</strong> -
<div>
Fear is an evolutionary adaptive emotion that serves to protect the organism from harm. Once a threat diminishes, fear should also dissipate as otherwise fear may become chronic and pathological. While threat (i.e., number of infections, hospitalizations and deaths) during the ongoing COVID-19 pandemic has substantially varied over time, it remains unclear whether fear has followed a similar pattern. To examine the development of fear of COVID-19 and investigate potential predictors for chronic fear, we conducted a large online longitudinal study (N = 2000) using the Prolific platform. Participants represented unselected residents of 34 different countries. The Fear of the Coronavirus Questionnaire (FCQ) and several other demographic and psychological measures were completed monthly between March and August 2020. Overall, we find that fear steadily decreased after a peak in April 2020. Additional analyses showed that elevated fear was predicted by region (i.e., North America), anxious traits, and media use.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://psyarxiv.com/xtu3f/" target="_blank">Pandemic panic? Results of a 6-month longitudinal study on fear of COVID-19</a>
</div></li>
<li><strong>Crystal structure and activity profiling of deubiquitinating inhibitors-bound to SARS-CoV-2 papain like protease revealed new allosteric sites for antiviral therapies</strong> -
<div>
Emerging variants of SARS-CoV-2 still threaten the effectiveness of currently deployed vaccines, and antivirals can prove to be an effective therapeutic option for attenuating it. The papain-like protease (PLpro) is an attractive target due to its sequence conservation and critical role in the replication and pathogenesis of SARS-CoV-2. PLpro also plays very important role in modulation of host immune responses by deubiquitinating (DUBs) or deISGylating host proteins. Thus, targeting PLpro serves as a two-pronged approach to abate SARS-CoV-2. Due to its structural and functional similarities with the host DUB enzymes, an in-house library of DUB inhibitors was constituted in this study. Five promising compounds exhibiting high binding affinities with the substrate binding site of PLpro were identified from a library of 81 compounds with in silico screening, docking, and simulation studies. Interestingly, lithocholic acid, linagliptin, teneligliptin, and flupenthixol significantly inhibited the proteolytic activity of PLpro. Each of these compounds abrogated in vitro replication of SARS-CoV-2 with EC50 values in the range of 5-21 micro M. In addition, crystal structure of SARS-CoV-2 PLpro and its complex with inhibitors have been determined that revealed their inhibitory mechanism. The findings of this study provide the proof-of-principle that the DUB inhibitors hold high potential as a new class of therapeutics against SARS-CoV-2. Additionally, this is the first study that has opened a new avenue towards not only targeting PLpro active site but also simultaneously directing towards restoration of antiviral immune response of the host for deterring SARS-CoV-2.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.11.11.516107v1" target="_blank">Crystal structure and activity profiling of deubiquitinating inhibitors-bound to SARS-CoV-2 papain like protease revealed new allosteric sites for antiviral therapies</a>
</div></li>
<li><strong>Attenuated humoral responses in HIV infection after SARS-CoV-2 vaccination are linked to global B cell defects and cellular immune profiles</strong> -
<div>
People living with HIV (PLWH) on suppressive antiretroviral therapy (ART) can have residual immune dysfunction and often display poorer responses to vaccination. We assessed in a cohort of PLWH (n=110) and HIV negative controls (n=64) the humoral and spike-specific B-cell responses following 1, 2 or 3 SARS-CoV-2 vaccine doses. PLWH had significantly lower neutralizing antibody (nAb) titers than HIV-negative controls at all studied timepoints. Moreover, their neutralization breadth was reduced with fewer individuals developing a neutralizing response against the Omicron variant (BA.1) relative to controls. We also observed a delayed development of neutralization in PLWH that was underpinned by a reduced frequency of spike-specific memory B cells (MBCs) and pronounced B cell dysfunction. Improved neutralization breadth was seen after the third vaccine dose in PLWH but lower nAb responses persisted and were associated with global, but not spike-specific, MBC dysfunction. In contrast to the inferior antibody responses, SARS-CoV-2 vaccination induced robust T cell responses that cross-recognized variants in PLWH. Strikingly, a subset of PLWH with low or absent neutralization had detectable functional T cell responses. These individuals had reduced numbers of circulating T follicular helper cells and an enriched population of CXCR3+CD127+CD8+ T cells after two doses of SARS-CoV-2 vaccination, which may compensate for sub-optimal serological responses in the event of infection. Therefore, normalisation of B cell homeostasis could improve serological responses to vaccines in PLWH and evaluating T cell immunity could provide a more comprehensive immune status profile in these individuals and others with B cell imbalances.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.11.11.516111v1" target="_blank">Attenuated humoral responses in HIV infection after SARS-CoV-2 vaccination are linked to global B cell defects and cellular immune profiles</a>
</div></li>
<li><strong>A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein</strong> -
<div>
The ongoing COVID-19 pandemic has had great societal and health consequences. Despite the availability of vaccines, infection rates remain high due to immune evasive Omicron sublineages. Broad-spectrum antivirals are needed to safeguard against emerging variants and future pandemics. We used mRNA display under a reprogrammed genetic code to find a spike-targeting macrocyclic peptide that inhibits SARS-CoV-2 Wuhan strain infection and also pseudoviruses containing spike proteins of SARS-CoV-2 variants or related sarbecoviruses. Structural and bioinformatic analyses reveal a conserved binding pocket between the receptor binding domain and other domains, distal to the ACE2 receptor-interaction site. Collectively, our data reveal a hitherto unexplored site of vulnerability in sarbecoviruses that can be targeted by peptides and potentially other drug-like molecules.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.11.11.516114v1" target="_blank">A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein</a>
</div></li>
<li><strong>Selection of long COVID symptoms influences prevalence estimates in a prospective cohort</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background: Studies on long COVID differ in the selection of symptoms used to define the condition. We aimed to assess to what extent symptom selection impacts prevalence estimates of long COVID. Methods: In a prospective cohort of patients who experienced mild to critical coronavirus disease 2019 (COVID-19), we used longitudinal data on the presence of 20 different symptoms to evaluate changes in the prevalence of long COVID over time when altering symptom selection. Results: Changing symptom selection resulted in wide variation in long COVID prevalence, even within the same study population. Long COVID prevalence at 12 months since illness onset ranged from 39.6% (95%CI=33.4-46.2) when using a limited selection of symptoms to 80.6% (95%CI=74.8-85.4) when considering any reported symptom to be relevant. Conclusions: Comparing the occurrence of long COVID is already complex due to heterogeneity in study design and population. Disparate symptom selection may further hamper comparison of long COVID estimates between populations. Harmonised data collection tools could be one means to achieve greater reproducibility and comparability of results.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.11.09.22282120v1" target="_blank">Selection of long COVID symptoms influences prevalence estimates in a prospective cohort</a>
</div></li>
<li><strong>Year-round RSV Transmission in the Netherlands Following the COVID-19 Pandemic - A Prospective Nationwide Observational and Modeling Study</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
A nationwide prospective study showed year-round RSV transmission in the Netherlands after an initial 2021 summer outbreak. The pattern was unprecedented and distinct from neighboring countries. Our dynamic simulation model suggests that this transmission pattern could be associated with waning immunity because of low RSV circulation during the COVID-19 pandemic.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.11.10.22282132v1" target="_blank">Year-round RSV Transmission in the Netherlands Following the COVID-19 Pandemic - A Prospective Nationwide Observational and Modeling Study</a>
</div></li>
<li><strong>Screening, diagnosis and hospitalization of breast and cervical cancer in Brazil from 2010 to 2022: a time-series study</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
In Brazil, during the pandemic caused by COVID-19, screening for breast and cervical cancers was postponed or interrupted due to the prevailing health conditions. These neoplasms, however, are responsible for high morbidity and mortality among women in Brazil and have a major impact on the quality of life of this population and on public health. Thus, this study aims to evaluate the epidemiological behavior of hospitalization for cervical and breast cancer in Brazilian women, as well as the trend of screening tests and diagnosis of breast and cervical cancer in the years 2010 to 2022 in Brazil. This is an ecological research of time series, based on secondary data obtained from information systems of the country, about hospital admissions for breast and cervical cancer and screening methods used for these tumors. The data were analyzed in the Joinpoint Regression Program, to obtain the linear regression and temporal analysis of the variables. As results, there is a decrease in hospitalization rates for cervical cancer between the years 2010 and 2015 and a subsequent increase in 2019. Regarding breast cancer, there was an increase in hospitalizations, until reaching a peak in 2019. For both, in the pandemic years, between 2020 and 2022, there is a decrease in Brazil and in all its regions. As for the tracking of these diseases, it was observed that the performance of mammograms and preventive tests showed a similar behavior, in which there is a higher supply of these tests until 2019 and a drop during the pandemic period. This leads to the conclusion that even though Brazil has several policies for screening and early diagnosis of these diseases, there is still instability in the offer of tests and that there was a precariousness in this area during the pandemic.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.11.09.22282147v1" target="_blank">Screening, diagnosis and hospitalization of breast and cervical cancer in Brazil from 2010 to 2022: a time-series study</a>
</div></li>
<li><strong>Heterogeneity and Risk-of-Biases are No Longer the Issues to Conclude the Effectiveness of Baricitinib in Reducing COVID-19 Related Mortality: A Systematic Review and Meta-Analysis of Eight Randomised Controlled Trials</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Background: Due to high heterogeneity and risk of bias (RoB) in previously published meta-analysis, a concrete conclusion on the efficacy of baricitinib in reducing mortality in COVID-19 patients was unable to form. Methods: Search engines PubMed/MEDLINE, ScienceDirect and other sources like preprints and reference lists were searched with appropriate keywords. The included evidence was graded with GRADEpro. The RoB, heterogeneity and meta-analysis were studied through RevMan 5.4.1 software. The heterogeneity was evaluated based on the generated p-value or I2 test. Results: Eight (8) RCTs were included in current analysis. Five studies had low RoB. Based on grading the evidence, the inclusion and exclusion of high RoB articles led to moderate and high certainty of evidence, respectively. Based on 8 RCTs (with high RoB), baricitinib statistically significantly reduced mortality where the risk ratio (RR) = 0.84 [95% CI: 0.76 to 0.92; p = 0.0002; I2 = 23%; p = 0.25]. The heterogeneity was insignificant but the RoB was high. We did subgroup analysis of low and high RoB articles and found out baricitinib statistically significantly reduced mortality with the RR = 0.68 [95% CI: 0.56 to 0.82; p &lt; 0.0001; I2 = 0%; p = 0.85] and RR = 0.89 [95% CI: 0.80 to 0.99; p = 0.04; I2 = 0%; p = 0.43], respectively. The heterogeneity was 0% with insignificant p-values in both subgroup analyses. The percentage of mortality reduction was 31.31% and 7.79%, respectively whereas it was 13.95% in main group analysis. Conclusion: With the presence of optimal sample size of 3944 from 5 low RoB studies which represents a minimum of 300 million population of people and with 0% of heterogeneity, the effectiveness of baricitinib in reducing the mortality in COVID-19 patients is concretely proven.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.11.07.22282055v1" target="_blank">Heterogeneity and Risk-of-Biases are No Longer the Issues to Conclude the Effectiveness of Baricitinib in Reducing COVID-19 Related Mortality: A Systematic Review and Meta-Analysis of Eight Randomised Controlled Trials</a>
</div></li>
<li><strong>Cotranslational formation of disulfides guides folding of the SARS CoV-2 receptor binding domain</strong> -
<div>
Many secreted proteins contain multiple disulfide bonds. How disulfide formation is coupled to protein folding in the cell remains poorly understood at the molecular level. Here, we combine experiment and simulation to address this question as it pertains to the SARS-CoV-2 receptor binding domain (RBD). We show that, whereas RBD can refold reversibly when its disulfides are intact, their disruption causes misfolding into a nonnative molten-globule state that is highly prone to aggregation and disulfide scrambling. Thus, non-equilibrium mechanisms are needed to ensure disulfides form prior to folding in vivo. Our simulations suggest that co-translational folding may accomplish this, as native disulfide pairs are predicted to form with high probability at intermediate lengths, ultimately committing the RBD to its metastable native state and circumventing nonnative intermediates. This detailed molecular picture of the RBD folding landscape may shed light on SARS-CoV-2 pathology and molecular constraints governing SARS-CoV-2 evolution.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.11.10.516025v1" target="_blank">Cotranslational formation of disulfides guides folding of the SARS CoV-2 receptor binding domain</a>
</div></li>
<li><strong>A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta</strong> -
<div>
Clinically licensed COVID-19 vaccines ameliorate viral infection by inducing vaccinee production of neutralizing antibodies that bind to the SARS-CoV-2 Spike protein to inhibit viral cellular entry (Walsh et al., 2020; Baden et al., 2021), however the clinical effectiveness of these vaccines is transitory as viral variants arise that escape antibody neutralization (Tregoning et al., 2021; Willett et al., 2022). Vaccines that solely rely upon a T cell response to combat viral infection could be transformational because they can be based on highly conserved short peptide epitopes that hold the potential for pan-variant immunity, but a mRNA-LNP T cell vaccine has not been shown to be sufficient for effective antiviral prophylaxis. Here we show that a mRNA-LNP vaccine based on highly conserved short peptide epitopes activates a CD8+ and CD4+ T cell response that prevents mortality in HLA-A*02:01 transgenic mice infected with the SARS-CoV-2 Beta variant of concern (B.1.351). In mice vaccinated with the T cell vaccine, 24% of the nucleated cells in lung were CD8+ T cells on day 7 post infection. This was 5.5 times more CD8+ T cell infiltration of the lungs in response to infection compared to the Pfizer-BioNTech Comirnaty(R) vaccine. Between days 2 and 7 post infection, the number of CD8+ T cells in the lung increased in mice vaccinated with the T cell vaccine and decreased in mice vaccinated with Comirnaty(R). The T cell vaccine did not produce neutralizing antibodies, and thus our results demonstrate that SARS-CoV-2 viral infection can be controlled by a T cell response alone. Our results suggest that further study is merited for pan-variant T cell vaccines, and that T cell vaccines may be relevant for individuals that cannot produce neutralizing antibodies or to help mitigate Long COVID.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.09.23.509206v3" target="_blank">A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta</a>
</div></li>
<li><strong>Health, socioeconomic and genetic predictors of COVID-19 vaccination uptake: a nationwide machine-learning study</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Reduced participation in COVID-19 vaccination programs is a key societal concern. Understanding factors associated with vaccination uptake can help in planning effective immunization programs. We considered 2,890 health, socioeconomic, familial, and demographic factors measured on the entire Finnish population aged 30 to 80 (N=3,192,505) and genome-wide information for a subset of 273,765 individuals. Risk factors were further classified into 12 thematic categories and a machine learning model was trained for each category. The main outcome was uptaking the first COVID-19 vaccination dose by 31.10.2021, which has occurred for 90.3% of the individuals. The strongest predictor category was labor income in 2019 (AUC evaluated in a separate test set = 0.710, 95% CI: 0.708-0.712), while drug purchase history, including 376 drug classes, achieved a similar prediction performance (AUC = 0.706, 95% CI: 0.704-0.708). Higher relative risks of being unvaccinated were observed for some mental health diagnoses (e.g. dissocial personality disorder, OR=1.26, 95% CI : 1.24-1.27 ) and when considering vaccination status of first-degree relatives (OR=1.31, 95% CI:1.31-1.32 for unvaccinated mothers) We derived a prediction model for vaccination uptake by combining all the predictors and achieved good discrimination (AUC = 0.801, 95% CI: 0.799-0.803). The 1% of individuals with the highest risk of not vaccinating according to the model predictions had an average observed vaccination rate of only 18.8%. We identified 8 genetic loci associated with vaccination uptake and derived a polygenic score, which was a weak predictor of vaccination status in an independent subset (AUC=0.612, 95% CI: 0.601-0.623). Genetic effects were replicated in an additional 145,615 individuals from Estonia (genetic correlation=0.80, 95% CI: 0.66-0.95) and, similarly to data from Finland, correlated with mental health and propensity to participate in scientific studies. Individuals at higher genetic risk for severe COVID-19 were less likely to get vaccinated (OR=1.03, 95% CI: 1.02-1.05). Our results, while highlighting the importance of harmonized nationwide information, not limited to health, suggest that individuals at higher risk of suffering the worst consequences of COVID-19 are also those less likely to uptake COVID-19 vaccination. The results can support evidence-informed actions for COVID-19 and other areas of national immunization programs.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.11.11.22282213v1" target="_blank">Health, socioeconomic and genetic predictors of COVID-19 vaccination uptake: a nationwide machine-learning study</a>
</div></li>
<li><strong>Assessing the spatial-temporal risks of SARS-CoV-2 infection for healthcare-workers in the hospital using behavioural indices from routine data</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The COVID-19 pandemic has emphasised the need to rapidly assess infection risks for healthcare workers within the hospital environment. Using data from the first year of the pandemic, we investigated whether an individuals COVID-19 test result was associated with behavioural markers derived from routinely collected hospital data two weeks prior to a test. The temporal and spatial context of behaviours were important, with the highest risks of infection during the first wave, for staff in contact with a greater number of patients and those with greater levels of activity on floors handling the majority of COVID-19 patients. Infection risks were higher for BAME staff and individuals working more shifts. Night shifts presented higher risks of infection between waves of COVID-19 patients. Our results demonstrate the epidemiological relevance of deriving markers of staff behaviour from electronic records, which extend beyond COVID-19 with applications for other communicable diseases and in supporting pandemic preparedness.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.11.10.22282176v1" target="_blank">Assessing the spatial-temporal risks of SARS-CoV-2 infection for healthcare-workers in the hospital using behavioural indices from routine data</a>
</div></li>
<li><strong>Cohort profile: A Quebec-based plasma donor biobank to study COVID-19 immunity (PlasCoV)</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Purpose Long-term humoral immunity to COVID-19 is not well understood owing to the continuous emergence of new variants of concern, the evolving vaccine- and infection-induced immunity, and the limited follow-up of previous studies. As the blood service in Quebec (Canada), we established in April 2021 a COVID-19-focused biobank. Participants As of January 2022, included 86,229 plasma samples from 15,502 regular donors (age range=18-84 years, female %=49.7%), for an average of 5.6 donations per donor. Nearly two thirds (65.6%) of biobank donors made at least 2 donations, with many donors having provided samples pre- and post-vaccination (3061 [19.75%]) or pre- and post-infection (131 [0.85%]), thus allowing longitudinal studies on vaccine- and infection-induced immunity. Findings to date Comparative analysis of the immune response after the first and second dose of the BNT162b2 COVID-19 vaccine among SARS-CoV-2 naive and previously infected individuals revealed that a single vaccine dose administered to previously infected individuals yields a maximal immune response. In contrast, SARS-CoV-2 naive individuals required two vaccine doses to produce a maximal immune response. Furthermore, the results of a four-phase seroprevalence study indicate that the anti-N antibody response wanes quite rapidly, so that up to one third of previously infected donors were seronegative for anti-N. Future plans This plasma biobank from frequent and motivated donors, and the longitudinal nature of the biobank, will provide valuable insights into the anti-SARS-CoV-2 immune response and its persistence in time, and the effect of vaccination and of viral variants on the specificity of the antiSARS-CoV-2 immune response.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.11.09.22282156v1" target="_blank">Cohort profile: A Quebec-based plasma donor biobank to study COVID-19 immunity (PlasCoV)</a>
</div></li>
<li><strong>A Digital Biomarker for Identifying Changes in Daily Activity Patterns</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Malnutrition and dehydration are strongly associated with increased cognitive and functional decline in people living with dementia (PLWD), as well as an increased rate of hospitalisations in comparison to their healthy counterparts. Extreme changes in eating and drinking behaviours can often lead to malnutrition and dehydration, accelerating the progression of cognitive and functional decline and resulting in a marked reduction in quality of life. Unfortunately, there are currently no established methods by which to objectively detect such changes. Here, we present the findings of a quantitative analysis conducted on in-home monitoring data collected from 73 households of PLWD using Internet of Things technologies. The Coronavirus 2019 (COVID-19) pandemic has previously been shown to have dramatically altered the behavioural habits, particularly the eating and drinking habits, of PLWD. Using the COVID-19 pandemic as a natural experiment, we show that there were significant changes in kitchen activities at the group level within a subset of 21 households of PLWD that were continuously monitored for 499 days, with an overall increase in day-time activities and a decrease in night-time activity observed in both single and multiple occupancy households. We further present preliminary results suggesting it is possible to proactively detect episodic and gradual changes in behaviours using remote monitoring data as a proxy for behaviours that cannot be directly measured. Together, these results pave the way to introduce improvements into the monitoring of PLWD in naturalistic settings and for shifting from reactive to proactive care.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.10.25.22281467v2" target="_blank">A Digital Biomarker for Identifying Changes in Daily Activity Patterns</a>
</div></li>
<li><strong>Parents’ Work Arrangements and Gendered Time Use During the COVID-19 Pandemic</strong> -
<div>
Objective: This study uses time diaries to examine how work arrangements shaped mothers’ and fathers’ time use at home and work during the COVID-19 pandemic. Background: The pandemic transformed home and work life for parents, disrupting employment and childcare. The shift to work from home offered more flexibility than the workplace to manage increased care burdens, but the lack of separation between work and family also likely contributed to more challenging work environments, especially among mothers. Method: This study relies on representative data from the 2017-2020 American Time Use Survey and matching to estimate changes in time use among parents working from home and the workplace in the pandemic relative to equivalent pre-pandemic parents. Results: Data showed no increase among working parents in activities in which childcare was the primary focus. Parents working from home during the pandemic, however, spent substantially more time on supervisory childcare, particularly in combination with paid work, and housework. Mothers working from home also changed their paid work schedules. Conclusion: Parents working from home responded to childcare demands through multitasking and schedule changes, especially mothers, with potential negative effects on work quality and stress. Parents in the workplace during the pandemic experienced smaller changes in time use, suggesting little flexibility to accommodate changes in family life. Implications: The pandemic has generated new inequalities between those with and without the flexibility to work from home, and potentially exacerbated gender inequalities among those working from home.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/preprints/socarxiv/xc9mw/" target="_blank">Parents’ Work Arrangements and Gendered Time Use During the COVID-19 Pandemic</a>
</div></li>
</ul>
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 Bivalent Booster Megastudy</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Behavioral: COVID Booster text messages<br/><b>Sponsor</b>:   University of Pennsylvania<br/><b>Enrolling by invitation</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Using a Community-level Just-in-Time Adaptive Intervention to Address COVID-19 Testing Disparities</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Behavioral: Multi-Level Multi-Component Intervention (MLI);   Behavioral: Community Just-In-Time Adaptive Intervention (Community JITAI)<br/><b>Sponsors</b>:   The University of Texas Health Science Center, Houston;   National Center for Advancing Translational Sciences (NCATS)<br/><b>Active, not recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Examining How a Facilitated Self-Sampling Intervention and Testing Navigation Intervention Influences COVID-19 Testing</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Behavioral: Facilitated Self-Sampling Intervention (FSSI);   Behavioral: Testing Navigation Intervention (TNI).;   Behavioral: Control<br/><b>Sponsors</b>:   The University of Texas Health Science Center, Houston;   National Center for Advancing Translational Sciences (NCATS)<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Assessing Performance of the Testing Done Simple Covid 19 Antigen Test</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Diagnostic Test: Testing Done Simple SARS CoV-2 Antigen Test<br/><b>Sponsors</b>:   Testing Done Simple;   Nao Medical Urgent Care<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: EuCorVac-19;   Biological: ChAdOx1<br/><b>Sponsor</b>:   EuBiologics Co.,Ltd<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Open Multicentre Study of the Safety and Efficacy Against COVID-19 of Nirmatrelvir/Ritonavir in the Adult Population</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: nirmatrelvir/ritonavir;   Drug: Standard of care<br/><b>Sponsors</b>:   Promomed, LLC;   Sponsor GmbH<br/><b>Completed</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Study Evaluating GS-5245 in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: GS-5245;   Drug: GS-5245 Placebo<br/><b>Sponsor</b>:   Gilead Sciences<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial</strong> - <b>Conditions</b>:   COVID-19;   Coronavirus Infections<br/><b>Interventions</b>:   Biological: LIBP-Rec-Vaccine;   Biological: BIBP-Rec-Vaccine;   Biological: placebo<br/><b>Sponsors</b>:   National Vaccine and Serum Institute, China;   China National Biotec Group Company Limited;   Lanzhou Institute of Biological Products Co., Ltd;   Beijing Institute of Biological Products Co Ltd.<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: GLB-COV2-043;   Drug: BNT162b2/COMIRNATY®<br/><b>Sponsor</b>:   GreenLight Biosciences, Inc.<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: Avacc 10;   Combination Product: Outer Membrane Vesicles (OMV) : OMV alone in vehicle;   Other: Placebo<br/><b>Sponsors</b>:   Intravacc B.V.;   Novotech (Australia) Pty Limited<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Phase Ⅱ/Ⅲ Trial of LYB001</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: LYB001;   Biological: Placebo<br/><b>Sponsor</b>:   Yantai Patronus Biotech Co., Ltd.<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19</strong> - <b>Condition</b>:   SARS-CoV-2 Infection<br/><b>Intervention</b>:   Drug: Nitric Oxide<br/><b>Sponsors</b>:   Sanotize Research and Development corp.;   Glenmark Pharmaceuticals Ltd. India<br/><b>Completed</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster</strong> - <b>Condition</b>:   COVID-19 Pandemic<br/><b>Interventions</b>:   Biological: Lyophilized COVID-19 mRNA Vaccine;   Drug: Sodium chloride<br/><b>Sponsors</b>:   Wuhan Recogen Biotechnology Co., Ltd.;   Shenzhen Rhegen Biotechnology Co., Ltd.;   Wuhan Rhegen Biotechnology Co., Ltd.<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Role of Tele-physical Therapy in Patients With Type 2 Diabetes Mellitus Following COVID-19 Infection.</strong> - <b>Conditions</b>:   Type 2 Diabetes Mellitus;   COVID-19<br/><b>Interventions</b>:   Other: Tele physical therapy;   Other: Patient educationa and Conventional exercises<br/><b>Sponsor</b>:   Prince Sattam Bin Abdulaziz University<br/><b>Completed</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Immunogenicity and Safety of ChulaCov19 BNA159 Vaccine as a Booster Dose in Adults</strong> - <b>Condition</b>:   COVID-19, SARS CoV 2 Infection<br/><b>Interventions</b>:   Biological: ChulaCov19 BNA159 vaccine (50 mcg);   Biological: Pfizer/BNT vaccine (30 mcg)<br/><b>Sponsors</b>:   Technovalia, Pty Ltd;   Chulalongkorn University;   Bionet Co., Ltd;   Southern Star Research Pty Ltd.<br/><b>Not yet recruiting</b></p></li>
</ul>
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Identification of novel inhibitors of high affinity iron permease (FTR1) through implementing pharmacokinetics index to fight against black fungus: An in silico approach</strong> - Mucormycosis is a life-threatening fungal infection, particularly in immunocompromised patients. Mucormycosis has been reported to show resistance to available antifungal drugs and was recently found in COVID-19 as a co-morbidity that demands new classes of drugs. In an attempt to find novel inhibitors against the high-affinity iron permease (FTR1), a novel target having fundamental importance on the pathogenesis of mucormycosis, 11,000 natural compounds were investigated in this study. Virtual…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Chicken interferon-induced transmembrane protein 1 promotes replication of coronavirus infectious bronchitis virus in a cell-specific manner</strong> - Interferon-induced transmembrane proteins (IFITMs) are broad-spectrum antiviral proteins that inhibit numerous virus infections by impeding viral entry into target cells. However, increasing evidence suggests diverse functions of IFITMs in virus infection, especially with the coronavirus. We analyzed the effect of chicken interferon-induced transmembrane proteins (chIFITMs) on coronavirus infectious bronchitis virus (IBV) infection in vitro. We demonstrated that the antiviral effects of IFITMs…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Design, Synthesis, and Biological Evaluation of Novel Ruxolitinib and Baricitinib Analogues for Potential Use Against COVID-19</strong> - The coronavirus pandemic known as COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), threatens public health worldwide. Approval of COVID-19 vaccines and antiviral drugs have greatly reduced the severe cases and mortality rate. However, the continues mutations of viruses are challenging the efficacies of vaccines and antiviral drugs. Drug repurposing campaign has identified two JAK1/2 inhibitors ruxolitinib and baricitinib as potential antiviral drugs. Ruxolitinib…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>SARS-CoV-2 at the Human-Animal Interface: Implication for Global Public Health from an African Perspective</strong> - The coronavirus disease 2019 (COVID-19) pandemic has become the most far-reaching public health crisis of modern times. Several efforts are underway to unravel its root cause as well as to proffer adequate preventive or inhibitive measures. Zoonotic spillover of the causative virus from an animal reservoir to the human population is being studied as the most likely event leading to the pandemic. Consequently, it is important to consider viral evolution and the process of spread within zoonotic…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Short 5’triphosphate RNA nCoV-L Induces a Broad-Spectrum Antiviral Response by Activating RIG-I</strong> - Small molecular nucleic acid drugs produce antiviral effects by activating pattern recognition receptors (PRRs). In this study, a small molecular nucleotide containing 5’triphosphoric acid (5’PPP) and possessing a double-stranded structure was designed and named nCoV-L. nCoV-L was found to specifically activate RIG-I, induce interferon responses, and inhibit duplication of four RNA viruses (Human enterovirus 71, Human poliovirus 1, Human coxsackievirus B5 and Influenza A virus) in cells. In…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Canine Coronavirus Activates Aryl Hydrocarbon Receptor during In Vitro Infection</strong> - The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that interacts with substrates, including microbial metabolites. Recent advances reveal that AhR is involved in the host response to coronaviruses (CoVs) infection. Particularly, AhR antagonists decrease the expression of angiotensin-converting enzyme 2 (ACE2) via AhR up-regulation, resulting in suppression of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in mammalian cells. Herein, we report…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant</strong> - The recently circulating SARS-CoV-2 Omicron BA.5 is rampaging the world with elevated transmissibility compared to the original SARS-CoV-2 strain. Immune escape of BA.5 was observed after treatment with many monoclonal antibodies, calling for broad-spectrum, immune-escape-evading therapeutics. In retrospect, we previously reported Kansetin as an ACE2 mimetic and a protein antagonist against SARS-CoV-2, which proved potent neutralization bioactivity on the Reference, Alpha, Beta, Delta, and…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Immunogenicity of an mRNA-Based COVID-19 Vaccine among Adolescents with Obesity or Liver Transplants</strong> - There are limited data regarding the immunogenicity of mRNA-based SARS-CoV-2 vaccine BNT162b2 among immunosuppressed or obese adolescents. We evaluated the humoral immune response in adolescents with obesity and adolescent liver transplant recipients (LTRs) after receiving two BNT162b2 doses. Sixty-eight participants (44 males; mean age 14.9 ± 1.7 years), comprising 12 LTRs, 24 obese, and 32 healthy adolescents, were enrolled. Immunogenicity was evaluated by anti-SARS-CoV-2 spike protein…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>In Silico Approach for the Evaluation of the Potential Antiviral Activity of Extra Virgin Olive Oil (EVOO) Bioactive Constituents Oleuropein and Oleocanthal on Spike Therapeutic Drug Target of SARS-CoV-2</strong> - Since there is an urgent need for novel treatments to combat the current coronavirus disease 2019 (COVID-19) pandemic, in silico molecular docking studies were implemented as an attempt to explore the ability of selected bioactive constituents of extra virgin olive oil (EVOO) to act as potent SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antiviral compounds, aiming to explore their ability to interact with SARS-CoV-2 Spike key therapeutic target protein. Our results suggest that…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Identification of Doxorubicin as Repurposing Inhibitory Drug for MERS-CoV PLpro</strong> - Middle East respiratory syndrome coronavirus (MERS-CoV), belonging to the betacoronavirus genus can cause severe respiratory illnesses, accompanied by pneumonia, multiorgan failure, and ultimately death. CoVs have the ability to transgress species barriers and spread swiftly into new host species, with human-to-human transmission causing epidemic diseases. Despite the severe public health threat of MERS-CoV, there are currently no vaccines or drugs available for its treatment. MERS-CoV…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Impact of <em>TMPRSS2</em> Expression, Mutation Prognostics, and Small Molecule (CD, AD, TQ, and TQFL12) Inhibition on Pan-Cancer Tumors and Susceptibility to SARS-CoV-2</strong> - As a cellular protease, transmembrane serine protease 2 (TMPRSS2) plays roles in various physiological and pathological processes, including cancer and viral entry, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Herein, we conducted expression, mutation, and prognostic analyses for the TMPRSS2 gene in pan-cancers as well as in COVID-19-infected lung tissues. The results indicate that TMPRSS2 expression was highest in prostate cancer. A high expression of TMPRSS2 was…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Homology Modeling and Molecular Dynamics-Driven Search for Natural Inhibitors That Universally Target Receptor-Binding Domain of Spike Glycoprotein in SARS-CoV-2 Variants</strong> - The rapid spread of SARS-CoV-2 required immediate actions to control the transmission of the virus and minimize its impact on humanity. An extensive mutation rate of this viral genome contributes to the virus’ ability to quickly adapt to environmental changes, impacts transmissibility and antigenicity, and may facilitate immune escape. Therefore, it is of great interest for researchers working in vaccine development and drug design to consider the impact of mutations on virus-drug interactions….</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong><em>Lentinus edodes</em> Polysaccharides Alleviate Acute Lung Injury by Inhibiting Oxidative Stress and Inflammation</strong> - Acute lung injury (ALI) is a kind of lung disease with acute dyspnea, pulmonary inflammation, respiratory distress, and non-cardiogenic pulmonary edema, accompanied by the mid- and end-stage characteristics of COVID-19, clinically. It is imperative to find non-toxic natural substances on preventing ALI and its complications. The animal experiments demonstrated that Lentinus edodes polysaccharides (PLE) had a potential role in alleviating ALI by inhibiting oxidative stress and inflammation, which…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ultra-Large-Scale Screening of Natural Compounds and Free Energy Calculations Revealed Potential Inhibitors for the Receptor-Binding Domain (RBD) of SARS-CoV-2</strong> - The emergence of immune-evading variants of SARS-CoV-2 further aggravated the ongoing pandemic. Despite the deployments of various vaccines, the acquired mutations are capable of escaping both natural and vaccine-induced immune responses. Therefore, further investigation is needed to design a decisive pharmacological treatment that could efficiently block the entry of this virus into cells. Hence, the current study used structure-based methods to target the RBD of the recombinant variant…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Broad Antiviral Effects of <em>Echinacea purpurea</em> against SARS-CoV-2 Variants of Concern and Potential Mechanism of Action</strong> - SARS-CoV-2 variants of concern (VOCs) represent an alarming threat as they show altered biological behavior and may escape vaccination effectiveness. Broad-spectrum antivirals could play an important role to control infections. The activity of Echinacea purpurea (Echinaforce^(®) extract, EF) against (i) VOCs B1.1.7 (alpha), B.1.351.1 (beta), P.1 (gamma), B1.617.2 (delta), AV.1 (Scottish), B1.525 (eta), and B.1.1.529.BA1 (omicron); (ii) SARS-CoV-2 spike (S) protein-pseudotyped viral particles and…</p></li>
</ul>
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
<script>AOS.init();</script></body></html>

383
archive-daily-dose/12 November, 2022.html Normal file
View File

@ -0,0 +1,383 @@
<!DOCTYPE html>
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
<meta charset="utf-8"/>
<meta content="pandoc" name="generator"/>
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
<title>12 November, 2022</title>
<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
</style>
<title>Daily-Dose</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><style>*{overflow-x:hidden;}</style><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="daily-dose">Daily-Dose</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-new-yorker">From New Yorker</a></li>
<li><a href="#from-vox">From Vox</a></li>
<li><a href="#from-the-hindu-sports">From The Hindu: Sports</a></li>
<li><a href="#from-the-hindu-national-news">From The Hindu: National News</a></li>
<li><a href="#from-bbc-europe">From BBC: Europe</a></li>
<li><a href="#from-ars-technica">From Ars Technica</a></li>
<li><a href="#from-jokes-subreddit">From Jokes Subreddit</a></li>
</ul>
<h1 data-aos="fade-right" id="from-new-yorker">From New Yorker</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Midterm Elections Deliver a Stunning Return to the Status Quo</strong> - The red wave never materialized, Trump’s handpicked candidates underperformed, some new faces emerged—but the country appears as evenly divided as ever. - <a href="https://www.newyorker.com/news/the-political-scene/the-midterm-elections-deliver-a-stunning-return-to-the-status-quo">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Unlikely Victory of John Fetterman</strong> - In the early hours of the morning, as it became clear that Fetterman had won his crucial Senate race, his watch party turned from tension to celebration. - <a href="https://www.newyorker.com/news/news-desk/the-unlikely-victory-of-john-fetterman">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The 2022 Midterm Elections: Live Results Map</strong> - The latest vote counts, news, and updates from the U.S. House, Senate, and gubernatorial races. - <a href="https://www.newyorker.com/news/midterm-election-2022/live-results-map-senate-house-governors-races">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Kingdom of Antonin Scalia</strong> - This Supreme Court has embraced his doctrine of judicial modesty in an imperious fashion. - <a href="https://www.newyorker.com/news/essay/the-kingdom-of-antonin-scalia">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Nate Cohn Explains Why This Year’s Midterms Broke The Mold</strong> - The Times’ polling guru digs into what we know so far about which issues motivated voters, and what he hopes to learn in the coming months. - <a href="https://www.newyorker.com/news/q-and-a/nate-cohn-explains-why-this-years-midterms-broke-the-mold">link</a></p></li>
</ul>
<h1 data-aos="fade-right" id="from-vox">From Vox</h1>
<ul>
<li><strong>Democrats still have a path to keep the House — but it’s tough</strong> -
<figure>
<img alt="An illustration of the houses of Congress floating in the air over a hand poised to catch them." src="https://cdn.vox-cdn.com/thumbor/2VVCjO-VJV_8P0SUVlfnCYFCvoA=/225x0:1576x1013/1310x983/cdn.vox-cdn.com/uploads/chorus_image/image/71612007/house_countrol_2.0.jpg"/>
<figcaption>
Christina Animashaun/Vox
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
It all depends on remaining mail ballots in several key states.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="bFCiwh">
Control of the House of Representatives remains unclear as of Saturday morning, as Republicans appear to have an edge but a path to a Democratic majority remains.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="AQ3H9N">
To win a majority, a party needs 218 seats. The totals for several close contests and races with many uncounted mail ballots remain in flux. But currently, Republican candidates lead in 221 districts and Democrats lead in 214.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="UnW8MM">
So to hold their majority, Democrats need to gain the lead in four House races where Republicans are currently ahead — as well as holding on to their own leads, some of which are quite narrow.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ncTV2k">
A Democratic takeover is probably not the likely outcome at this point, but it is possible. One contest where a Republican previously led, in Maryland’s Sixth District, flipped to Democrats Friday, when Rep. David Trone (D) was called the winner. There are several other uncalled contests, particularly in California, where only about half the vote has been counted and tallies of the remaining mail ballots could change the leads.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="jWwiRp">
The catch is that Democrats’ small leads in other close races are far from secure. In recent days, Rep. Lauren Boebert (R-CO), who unexpectedly trailed her Democratic challenger, regained a small lead. And in four other uncalled contests, the Democrat is leading by less than 2 percentage points. So a lot would still have to go right for Democrats for the GOP’s takeover to be thwarted.
</p>
<h3 id="ACMuqh">
The key contests Democrats might hope to flip
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="vGKrcI">
There are 10 uncalled House contests where Republicans currently lead, so for a majority, Democrats would need to win four of those. And their hopes overwhelmingly hinge on whether slow tallies of mail-in ballots could shift outcomes in their favor.
</p>
<ul>
<li id="VhA0OG">
One possibility is <strong>Colorado’s Third District</strong>, the site of a potential shocking upset against Boebert. She is leading her Democratic challenger Adam Frisch by a little over a thousand votes, with more to tally — as well as <a href="https://www.denverpost.com/2022/11/10/lauren-boebert-colorado-election-results-adam-frisch-recount/">potential “cures”</a> for mail ballots that were initially<strong> </strong>rejected.
</li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="nnZ3RA">
In <strong>Oregon’s Fifth District</strong>, progressive Jamie McLeod-Skinner (D), who defeated a moderate incumbent in the Democratic primary, is currently trailing Lori Chavez-DeRemer (R) by 2.4 percentage points, with about one-quarter of the vote still uncounted.
</li>
<li id="YotKzg">
In <strong>New York’s 22nd District</strong>, an open seat contest to replace the retiring moderate Rep. John Katko (R), Republican Brandon Williams <a href="https://www.nytimes.com/interactive/2022/11/08/us/elections/results-new-york-us-house-district-22.html">leads by 1.6 percentage points</a>.
</li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="JYvS63">
Mail could also be a factor in <strong>Arizona’s Sixth District</strong>, where Republican Juan Ciscomani’s lead over Democrat Kristen Engel shrank to less than 1 percentage point Friday.
</li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="q3E4Dk">
But their hopes will probably hinge on California, another heavily vote-by-mail state, where there are several uncalled races where Republicans currently lead, and only about half the vote has been counted.
</p>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="7pGpz7">
The <strong>California 13th District’s </strong>open seat contest looks promising for Democrats to flip since On Saturday morning, Republican John Duarte was leading by only a tiny margin over Democrat Adam Gray (less than 100 votes), and just over 60 percent of the vote is counted.
</li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="hBkfSQ">
Rep. David Valadao (R) represents <strong>California’s 22nd District</strong>, which Joe Biden won handily, and he has been through this before. In 2018, he led his Democratic challenger by 8 points on election night, but as the mail count slowly came in, that lead vanished, and he fell behind on November 26 and wouldn’t regain his lead. (He won the seat back in 2020.) This time his lead already shrank from 8 points to 5 points. Will history repeat itself?
</li>
<li id="Y9JfDv">
<strong>California’s Third District</strong> and <strong>California’s 41st District</strong> both narrowly went for Trump in 2020, and Republican candidates Kevin Kiley (CA-03) and Rep. Ken Calvert (CA-41) <a href="https://www.nytimes.com/interactive/2022/11/08/us/elections/results-california-us-house-district-3.html">have</a> <a href="https://twitter.com/DecisionDeskHQ/status/1590762097423843328">single-digit</a> leads, with about half of the vote uncounted.
</li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="QxmKHX">
Finally, <strong>California’s 27th District</strong> and <strong>45th District</strong> feature Republican incumbents — Mike Garcia (CA-27) and Michelle Steel (CA-45) — who represent districts Biden won but who currently lead handily. Their final margins are expected to get closer, though it’s not clear whether the untallied votes will be sufficient to change the outcome.
</li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="5pieE9">
So those are Democrats’ hopes — to be saved by mail ballots and California’s slow counting process again. Still, it’s worth noting that though the conventional wisdom is that late-counted mail ballots benefit Democrats, that is not necessarily true in every state or district. (Washington and California have nonpartisan primaries, and in some of these, Republicans gained ground as mail ballots were counted this year.)
</p>
<h3 id="MvhFmr">
But Democrats would also need to hold on in their own tight races
</h3>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="YAwEEs">
Having five contests flip where Republicans currently lead isn’t exactly easy, but it is possible considering how close some of those races are and how many mail ballots haven’t been counted.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="HdEa2R">
Yet the extra challenge Democrats face is that they need to hold on to their own leads, including in some very tight races. That isn’t a sure lead, and they already saw leads in two contests (CO-03 and CA-41) slip away midweek.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="znmCeH">
The other districts where Democratic leads may be a bit shaky include:
</p>
<ul>
<li id="8sw2FS">
<strong>Washington’s Third District</strong>, a Republican-leaning district where Trump-critical Rep. Jaime Herrera Beutler (R) failed to advance from the top-two primary. The general election pits Trump-endorsed Joe Kent (R) against Marie Gluesenkamp Pérez (D), and while Perez <a href="https://www.nytimes.com/interactive/2022/11/08/us/elections/results-washington-us-house-district-3.html">currently leads</a> by about 1.8 percentage points, with 30 percent of the vote remaining uncounted.
</li>
<li id="SmwgzY">
<strong>Arizona’s First District</strong>, where redistricting put Rep. David Schweikert (R) in narrowly Biden-leaning territory. His challenger, Jevin Hodge (D), leads by about 1.3 percentage points, but again, <a href="https://www.nytimes.com/interactive/2022/11/08/us/elections/results-arizona-us-house-district-1.html?action=click&amp;pgtype=Article&amp;state=default&amp;module=election-results&amp;context=election_recirc&amp;region=Scoreboard">many uncounted mail ballots</a> remain.
</li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="YBQOWw">
<strong>Colorado’s Eighth District</strong>, which was newly created after redistricting. Yadira Caraveo (D) initially led the count, but the race since tightened dramatically, and she’s now ahead by just 0.73 percentage points.
</li>
<li id="DR6RoN">
<strong>Oregon’s Sixth District</strong>, a new Democratic-leaning district that saw a <a href="https://www.nytimes.com/interactive/2022/11/08/us/elections/results-oregon-us-house-district-6.html">bitter and expensive primary fight</a> won by Andrea Salinas (D). Salinas <a href="https://www.nytimes.com/interactive/2022/11/08/us/elections/results-oregon-us-house-district-6.html">leads</a> her GOP opponent by about 1.7 percentage points, with about 40 percent of the vote uncounted.
</li>
</ul>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="YkVIqi">
In addition, Rep. Mary Peltola (D-AK) currently leads <strong>Alaska’s at-large district</strong> and Rep. Jared Golden leads <strong>Maine’s Second District</strong>, but their fates will be decided by <a href="https://www.vox.com/22443775/ranked-choice-voting-explained-new-york-strategy">ranked-choice voting</a>, after lower-performing candidates in those races are eliminated and their ballots are reallocated to the voters’ second choice.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="iCJ6ym">
If some of these Democratic leads slip away in favor of Republicans, it’s possible the House will be called for the GOP relatively soon. But if Democrats hang on here and start gaining ground in contests where Republicans are up, House control could take weeks to determine, as California and other states deal with the slow process of processing and counting many thousands of mail ballots. Buckle up.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="nSE6Zd">
<em><strong>Update, November 12, 7:35 am: </strong></em><em>This story was originally published on November 10 and has been updated with election calls and race counts.</em>
</p></li>
<li><strong>This flu season is looking really scary, in one chart</strong> -
<figure>
<img alt="" src="https://cdn.vox-cdn.com/thumbor/0XzA0d9hvK2ASLgSD2A1XtWeBSc=/240x0:1680x1080/1310x983/cdn.vox-cdn.com/uploads/chorus_image/image/71618498/flu_border_board_4mod2.0.jpg"/>
<figcaption>
Christina Animashaun/Vox; Getty Images
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Here’s how to prepare for it.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="XS0rzB">
Flu season is here — and early red flags suggest it’s on track to be very, very bad. The latest data from the Centers for Disease Control and Prevention’s (CDC’s) <a href="https://www.cdc.gov/flu/weekly/index.htm?utm_source=substack&amp;utm_medium=email">Flu View</a> report show extraordinarily high numbers of positive flu tests reported to the agency from labs around the US. As of November 5, nearly 14,000 positive flu tests had been reported, as shown in the orange line on the below chart. That’s more than 12 times the number reported at the same time in 2019 (shown in the black line).
</p>
<figure class="e-image">
<img alt=" " src="https://cdn.vox-cdn.com/thumbor/ybTEghmAVsojC59lBCmVE9vB7Ys=/800x0/filters:no_upscale()/cdn.vox-cdn.com/uploads/chorus_asset/file/24189160/THDeX_flu_is_spreading_early_and_extraordinarily_quickly.png"/>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="I64ZJz">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="dTEfQl">
This year’s early and meteoric rise in flu transmission is at least somewhat related to the fact that more people are being tested for the flu than during previous years. Over the past five weeks, nearly twice as many flu tests were done at clinical labs nationwide as during the same period last year (about 460,000 versus 254,000). More testing means more cases will get picked up.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Nsx7Jb">
But there are other signs that these numbers represent real and very scary trends.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="c0futf">
For starters, a much higher proportion of flu tests are turning up positive than in previous years: During past bad flu seasons, test positivity has topped out around <a href="https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html">3.6 percent</a>, but last week, nearly <a href="https://www.cdc.gov/flu/weekly/index.htm">13 percent</a> of flu tests were positive. When a higher proportion of tests are positive, that means more people who are feeling sick actually have the flu than in past years.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="bBPo9d">
Concerning signals are also coming from doctors’ offices and hospitals. At this time of year, only 1 to 2 percent of patients in outpatient clinics generally report flu-like illnesses. But right now, that number is up to <a href="https://www.cdc.gov/flu/weekly/weeklyarchives2022-2023/images/ILI44_small.gif">5 and a half percent</a>, according to CDC. Not all of those patients actually have the flu — many might have RSV or other infections — but in combination with the flu testing numbers, it’s worrisome.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="3Bz4Hl">
Additionally, more than <a href="https://gis.cdc.gov/grasp/FluView/FluHospRates.html">five times as many people have been hospitalized for the flu</a> so far this season than at the same point in any of the last 10 years. And unlike RSV, which poses the biggest threat to the youngest and oldest, the severe disease flu causes is more evenly spread across age groups. About one-third of the people who’ve been hospitalized for flu this year were 65 or older, while another quarter were ages 18 to 49.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="LeFxhx">
These are especially worrisome signs given the health care <a href="https://www.vox.com/science-and-health/2022/11/4/23437303/rsv-nurses-staffing-workforce-orange-county-medical-healthcare-health-care">workforce strain we’ve already seen during the ongoing RSV surge</a>. And this early start doesn’t suggest this flu wave will be a flash in the pan. The flu is currently worst in the <a href="https://gis.cdc.gov/grasp/fluview/main.html">southeastern US</a>, but that will almost certainly change as the air gets colder and the virus migrates northward. Plus, cases haven’t peaked this early since 2009-10’s <a href="https://www.cdc.gov/flu/pandemic-resources/2009-h1n1-pandemic.html">no good, very bad H1N1 flu pandemic</a>.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="YZGYyZ">
The good news: There’s a lot you can do to protect yourself from the flu. This year’s flu vaccine is widely available and free with most insurance plans. And because both of the dominant flu strains <a href="https://www.cdc.gov/flu/weekly/index.htm">currently circulating</a> were included in <a href="https://www.fda.gov/vaccines-blood-biologics/lot-release/influenza-vaccine-2022-2023-season?utm_source=substack&amp;utm_medium=email">this year’s vaccine formulation</a>, there’s hope the shot will help prevent severe illness in people who get it.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="KXBYBy">
There’s also medicine to treat the flu, so if you’re sick and <a href="https://www.cdc.gov/flu/treatment/whatyoushould.htm#box">at risk for flu complications</a>, seek medical care early.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="s000yb">
And all that masking, ventilating, and air-filtering we learned to do during the pandemic does a lot to prevent flu transmission (not to mention all the other respiratory nasties out there).
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="h0RZRL">
Flu transmission actually<strong> </strong><a href="https://www.vox.com/science-and-health/22272237/flu-cases-down-historic-what-does-it-mean">dropped dramatically during the pandemic</a>. In the chart above, look at the blue lines, which represent cases reported over the last two years. You can see that there were very few positive tests in 2020, when mitigation measures — like widespread masking — were still in place and most kids weren’t in school buildings. Transmission picked up in 2021, but was on track with prior seasons — and was probably curbed beginning late in the year due to increased masking and social distancing in response to the omicron surge of Covid-19.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="7u1V1V">
This year’s start to the flu season is scary. But we can still take steps to flatten this curve.
</p></li>
<li><strong>Elon Musk, master businessman, can’t make up his mind</strong> -
<figure>
<img alt="Elon Musk walking into Twitter headquarters carrying a bathroom sink." src="https://cdn.vox-cdn.com/thumbor/OeR2stnGGonGErCBJBoQ7dIn16g=/733x0:3000x1700/1310x983/cdn.vox-cdn.com/uploads/chorus_image/image/71618435/1244262469.0.jpg"/>
<figcaption>
So far, Musk seems better at breaking Twitter than fixing it. | Twitter account of Elon Musk/AFP via Getty Images
</figcaption>
</figure>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
All the times Twitter’s Chief Flip-Flopper has gone back on his word.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="1668027134.010179">
Since <a href="https://www.vox.com/recode/2022/4/14/23024962/elon-musk-twitter-43-billion-private-analysis">Elon Musk first offered to buy Twitter this spring</a>, it appears that the billionaire has had a very hard time deciding just what to do with it. It seems as though every time he makes a grand pronouncement about the social media platform, he ends up walking it back. He’s changed his mind on everything from buying Twitter in the first place to what color its signature check marks should be, and he’s done so in a spectacularly public way. Workers at the social media platform — those who are left after <a href="https://www.vox.com/recode/2022/11/8/23444660/twitter-elon-musk-layoffs-stripe">massive layoffs</a> — are reportedly pulling <a href="https://www.theverge.com/2022/11/7/23446262/elon-musk-twitter-paywall-possible">20-hour days</a> to follow Musk’s ever-changing whims. He’s flip-flopped on so many things, it’s tough to keep track. Here’s a running list. Stay tuned for more.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="5mlMoG">
<strong>Flip-flop:</strong> Buying Twitter<br/><strong>How long before he changed his mind:</strong> Three months (from bid to officially trying to get out of the bid)<br/><strong>What happened: </strong>After months of buying up Twitter stock, Musk put in an unsolicited bid to buy Twitter in April for $43 billion or $54.20 a share, which the company accepted later that month. However, right away, Musk began hemming and hawing about the deal. He officially tried to get out of it in <a href="https://www.cnn.com/2022/07/08/tech/elon-musk-twitter-deal-exit/index.html">July</a> by saying the company misrepresented the number of bots on the platform. But faced with a potentially <a href="https://www.vox.com/the-goods/2022/10/5/23389103/elon-musk-twitter-buy-trial-scrutiny">grueling trial</a>, which would have exposed a lot of his personal communication and which he wasn’t guaranteed to win, Musk agreed to go through with the deal in <a href="https://www.vox.com/recode/2022/10/27/23424938/elon-musk-own-twitter-deal-closes-what-will-change-superapp-layoffs-free-speech-parag-agrawal">October</a>, three months after he tried to rescind it and six months after he sought to buy it in the first place.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="SmzrQd">
<strong>Mini flip-flop: </strong>When Musk became its largest shareholder, Twitter asked him to join its board of directors, an offer he <a href="https://www.bloomberg.com/news/articles/2022-04-05/twitter-names-musk-to-board-saying-he-s-exactly-what-we-need">accepted</a> then <a href="https://www.cnbc.com/2022/04/11/elon-musk-decides-not-to-join-twitter-board-says-ceo-parag-agrawal.html">declined</a> a few days later.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="xEvWIs">
<strong>Flip-flop:</strong> Adding checkmarks to Twitter Blue <br/><strong>How long before he changed his mind:</strong> Two days (from launch to suspension)<br/><strong>What happened: </strong>Musk had been talking about upgrading <a href="https://www.vox.com/recode/2022/11/4/23438917/twitter-verifications-blue-check-elon-musk">Twitter Blue</a> — a premium version of the app — since he bought Twitter in October, making it his first product priority after taking over. His idea was to let anyone who wants one buy a blue check mark, which is a badge on the Twitter profiles of public figures (like celebrities, journalists, and politicians) indicating that the person is who they say they are. This upset a lot of already blue-checked people, including author Stephen King of all people, who Musk publicly tried to negotiate with over price — going down from $20 to $8 a month. These new check marks, unlike the free ones that notable figures had pre-Musk, <a href="https://twitter.com/esthercrawford/status/1590109530452815872">don’t verify identity</a>, just that someone has $8 to spare each month, which means anyone paying could pretend to be someone else.
</p>
<div id="pcTLNz">
<blockquote class="twitter-tweet">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" dir="ltr" lang="en">
$20 a month to keep my blue check? Fuck that, they should pay me. If that gets instituted, I’m gone like Enron.
</p>
— Stephen King (<span class="citation" data-cites="StephenKing">@StephenKing</span>) <a href="https://twitter.com/StephenKing/status/1587042605627490304?ref_src=twsrc%5Etfw">October 31, 2022</a>
</blockquote></div></li>
</ul>
<div id="iBxnxM">
<blockquote class="twitter-tweet">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" dir="ltr" lang="en">
We need to pay the bills somehow! Twitter cannot rely entirely on advertisers. How about $8?
</p>
— Elon Musk (<span class="citation" data-cites="elonmusk">@elonmusk</span>) <a href="https://twitter.com/elonmusk/status/1587312517679878144?ref_src=twsrc%5Etfw">November 1, 2022</a>
</blockquote>
</div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="IsrX6M">
The company <a href="https://www.theverge.com/2022/11/9/23448317/elon-musk-twitter-blue-verification-live-ios">rolled check marks into the upgraded Twitter Blue feature</a> on iOS on Wednesday, November 9. As many expected, chaos ensued. Fake but verified accounts popped up everywhere, from pharmaceutical giant Ely Lilly (which falsely claimed insulin was free), to Florida governor Ron DeSantis (which called Trump a “little bitch”) to <a href="https://twitter.com/jesus">Jesus</a>, who is very funny and is not actually a parody risk. Some of these offending posts stayed up for hours.
</p>
<div id="iCvyQC">
<blockquote class="twitter-tweet">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" dir="ltr" lang="en">
Who has two thumbs and verified?
</p>
— Jesus Christ (<span class="citation" data-cites="jesus">@jesus</span>) <a href="https://twitter.com/jesus/status/1590405986925543424?ref_src=twsrc%5Etfw">November 9, 2022</a>
</blockquote>
</div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="wlSTtt">
By Friday, November 11, the company has reportedly <a href="https://twitter.com/zoeschiffer/status/1591081913166745601">suspended</a> the launch of Twitter Blue “to help address impersonation issues.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Bp9uo3">
It’s also not clear yet if actually verified people who previously had checks will get to keep those checks.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="naoP4z">
<strong>Flip-flop:</strong> Gray checkmarks<br/><strong>How long before he changed his mind:</strong> Less than a day (from rollout to disappearing)<br/><strong>What happened: </strong>On the morning of Wednesday, November 9, Twitter began rolling out gray check marks for certain celebrities and publishers. People had worried that it would be difficult to distinguish between those who had blue check marks because they were public figures and those who were just paying for the blue check, and the gray checks were apparently the solution. Hours later, the <a href="https://www.theverge.com/2022/11/9/23449122/twitter-official-verified-gray-checkmark-verification">gray checks disappeared</a>. Musk, in Musk fashion, tweeted the news as a response to someone wondering where their gray check had gone, saying, “I just killed it.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="L2XmT7">
One day later, the gray checks were back, this time only for <a href="https://twitter.com/ZoeSchiffer/status/1591082807237185539?s=20&amp;t=xqwL0di2af6n4UyEm00EGQ">advertisers</a>.
</p>
<div id="B1GssJ">
<blockquote class="twitter-tweet">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" dir="ltr" lang="en">
I just killed it
</p>
— Elon Musk (<span class="citation" data-cites="elonmusk">@elonmusk</span>) <a href="https://twitter.com/elonmusk/status/1590383366213611522?ref_src=twsrc%5Etfw">November 9, 2022</a>
</blockquote>
</div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="LATN2V">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="zajxlx">
<strong>Flip-flop:</strong> Firing Twitter employees<br/><strong>How long before he changed his mind:</strong> Two days (from firing to calling some back)<br/><strong>What happened: </strong>Musk began massive layoffs in the middle of the night on Thursday, November 3, and by Friday half the company — roughly 3,700 workers — had been fired. By Saturday, Platformer’s Casey Newton <a href="https://twitter.com/caseynewton/status/1589075543420325888">reported</a> the company had begun asking some of those workers to come back. Bloomberg <a href="https://www.bloomberg.com/news/articles/2022-11-06/twitter-now-asks-some-fired-workers-to-please-come-back">later reported dozens of laid-off employees</a> were asked to return. Apparently the layoffs were so enormous and haphazard, people had been laid off by <a href="https://www.bloomberg.com/news/articles/2022-11-06/twitter-now-asks-some-fired-workers-to-please-come-back">mistake</a>.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="WjZSs6">
<strong>Flip-flop:</strong> Parody accounts<br/><strong>How long before he changed his mind:</strong> About a week (from “comedy!” to “it’s not funny when you make fun of me”)<br/><strong>What happened: </strong>When Musk purchased Twitter, he <a href="https://twitter.com/MrBeast/status/1586105245997977601">tweeted</a> “comedy is now legal on Twitter.” Apparently, he does not consider parody to be comedy. After a number of accounts spoofed Musk by changing their display names to “Elon Musk” and using his profile picture, Musk <a href="https://twitter.com/elonmusk/status/1589390597798125568">stated</a> accounts would be suspended if they parodied another without specifying they were a parody. That led to the suspension of numerous accounts, including that of celebrities like <a href="https://www.theguardian.com/technology/2022/nov/07/twitter-will-ban-permanently-suspend-impersonator-accounts-elon-musk-says-as-users-take-his-name">Kathy Griffin</a>, Sarah Silverman, and <a href="https://www.rollingstone.com/culture/culture-news/twitter-suspends-accounts-parodying-elon-musk-1234625867/">Rich Sommer</a> from <em>Mad Men</em>.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="hbk9VB">
When Twitter rolled out Blue and parody accounts could now be verified, Musk made the parody guidelines stronger, asking parody accounts to list that they’re parody in their account name and their bio. For a time, those verified under Twitter’s legacy policy were unable to change their display names, leaving people like Doja Cat <a href="https://www.insider.com/doja-cat-begs-elon-musk-change-twitter-name-back-2022-11">stuck</a> with “christmas.” As The Verge <a href="https://www.theverge.com/2022/11/7/23446171/screen-name-twitter-musk-parody-whoops">pointed out</a>, this made it very hard to mark one’s account as a parody. (Musk has since fixed the issue and Doja Cat’s display name is currently “fart.”)
</p>
<div id="QOFC9T">
<blockquote class="twitter-tweet">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" dir="ltr" lang="en">
i don’t wanna be christmas forever <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw"><span class="citation" data-cites="elonmusk">@elonmusk</span></a> please help i’ve made a mistake
</p>
— fart (<span class="citation" data-cites="DojaCat">@DojaCat</span>) <a href="https://twitter.com/DojaCat/status/1590592859853684736?ref_src=twsrc%5Etfw">November 10, 2022</a>
</blockquote>
</div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="YkAfil">
<strong>Flip-flop: </strong>Not turning Twitter into a “free-for-all hellscape”<br/><strong>How long before he changed his mind: </strong>A few hours (from tweet to delete)<br/><strong>What happened:</strong> Just a few days after Musk took over Twitter and reassured advertisers he wouldn’t turn Twitter into a <a href="https://www.wsj.com/articles/elon-musk-will-face-an-early-twitter-challenge-preventing-advertiser-flight-11666871828">“free-for-all hellscape,” </a>he decided it would be a good time to start spreading some misinformation firsthand.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="9EqDvI">
Musk <a href="https://www.nytimes.com/2022/10/30/business/musk-tweets-hillary-clinton-pelosi-husband.html">replied to a tweet by Hillary Clinton</a> condemning Republicans for spreading conspiracy theories after a violent attack on Paul Pelosi, the husband of Democratic Speaker of the House Nancy Pelosi. Musk, taking a “just-asking-questions” attitude, wrote that “there is a tiny possibility there might be more to this story” and linked to an article by an outlet known for spreading fake news. It claimed, without evidence, that Pelosi was drunk at the time of the assault and “in a dispute with a male prostitute.”
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="oM45N1">
After facing immediate widespread backlash by everyone from Jimmy Kimmel to the VP of the Anti-Defamation League, <a href="https://www.washingtonpost.com/technology/2022/10/30/musk-deleted-tweet-pelosi/">Musk deleted the tweet</a> in just a few hours.
</p>
<div id="sbNMID">
<blockquote class="twitter-tweet">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" dir="ltr" lang="en">
It is sad to see <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw"><span class="citation" data-cites="elonmusk">@elonmusk</span></a> expunge and drive away so much talent at <a href="https://twitter.com/Twitter?ref_src=twsrc%5Etfw"><span class="citation" data-cites="Twitter">@Twitter</span></a> and push safety aside. I continue to think the below is a solid formula for an approach to the business but he is not doing what I thought he would. He is totally flailing and causing way more pain. <a href="https://t.co/XN3R8NQfSS">https://t.co/XN3R8NQfSS</a>
</p>
— Jessica Lessin (<span class="citation" data-cites="Jessicalessin">@Jessicalessin</span>) <a href="https://twitter.com/Jessicalessin/status/1590831770064551936?ref_src=twsrc%5Etfw">November 10, 2022</a>
</blockquote>
</div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="gZZWBY">
Musk’s constant flip-flopping is undermining the almost mythical aura surrounding the billionaire, often considered a visionary innovator and businessman. Twitter isn’t the same as launching rockets into space or creating an electric car company, but that doesn’t mean it’s not challenging. Watching his fumbling at Twitter play out on a global stage shows that Musk was much better at trolling Twitter when he didn’t own the place.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="WSYI3W">
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="yklpm1">
</p>
<h1 data-aos="fade-right" id="from-the-hindu-sports">From The Hindu: Sports</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Manu Gandas survives scare on the final hole to defend title</strong> -</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>‘FIFA Uncovered’ review: Netflix documentary traces FIFA’s power struggles and what it takes to host a World Cup</strong> - The Netflix series exposes Blatter’s role in turning FIFA from a non-profit organisation to a multi-million dollar family, the corrupt alliances that secure FIFA World Cup bids, and how football walks an ethical tightrope</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>1992 the flavour as Pakistan looks to repeat history and England seeks to rewrite it</strong> - The teams will draw inspiration from their semifinal exploits that came after gut-wrenching defeats in the Super 12s</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>F1 | Haas' Magnussen pulls off sensational pole position at Brazilian GP</strong> - Kevin Magnussen registered the first pole position of his career, while Red Bull’s Max Verstappen came second and Mercedes’ George Russell third in Sao Paulo</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>T20 World Cup final preview | History favours Pakistan, form with England</strong> - Just like everyone wants a slice of 1992 from Babar Azam’s Pakistan, the core of this current English team also has a date with history on Australian soil as the two sides face off in the 2022 T20 World Cup final</p></li>
</ul>
<h1 data-aos="fade-right" id="from-the-hindu-national-news">From The Hindu: National News</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Squads in action to expose ‘unfair’ hike in prices of essential commodities</strong> - Series of inspections expose incidents in which traders charge exorbitant prices for rice brands</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Seed and agro-diversity of India on display at Kisan Swaraj Sammelan</strong> -</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>BJP govt delaying assembly polls in J&amp;K to continue its proxy rule: AAP</strong> - Strongly condemning the escalation in militant activities, the AAP leader called upon the Centre to hold the assembly polls at the earliest</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>BJP announces candidate for Padmapur by-poll ahead of BJD, Cong</strong> - The saffron party is in an upbeat mood after the win and its naming of the candidate before other parties is considered an advantage</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Over 3,000 vocational higher secondary students get placement every year in Kerala</strong> - Through the career guidance and counselling cell under the General Education department</p></li>
</ul>
<h1 data-aos="fade-right" id="from-bbc-europe">From BBC: Europe</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ukraine war: Celebrations as Kyiv takes back key city Kherson</strong> - The Russian withdrawal is hailed as a victory, but Ukraine’s foreign minister says the “war goes on”.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Kherson biggest Russian loss since withdrawal from outside Kyiv</strong> - Moscow’s pullback from Kherson caps a stunning three-month change of fortune for the Ukrainians.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Sicily’s rich olive pickings - the fruit of Italy’s migrant exploitation</strong> - The African migrants living in squalor and picking produce for gangmasters in Italy.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Banksy unveils Ukraine gymnast mural on building shelled by Russia</strong> - The anonymous graffiti artist paints murals on buildings destroyed by Russian artillery attacks.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Putin can’t escape fallout from Russian retreat in Ukraine</strong> - The BBC’s Steve Rosenberg on the mood in Russia following its army’s withdrawal from Kherson.</p></li>
</ul>
<h1 data-aos="fade-right" id="from-ars-technica">From Ars Technica</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>“Dark ships” emerge from the shadow of the Nord Stream pipeline mystery</strong> - Satellite monitors found 2 vessels with their trackers turned off in area of explosions. - <a href="https://arstechnica.com/?p=1897100">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>2022 Apple TV 4K review: HDR10+ rounds out an already excellent streaming box</strong> - A lower price makes this mostly unchanged device much more appealing. - <a href="https://arstechnica.com/?p=1897225">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Southeast US has hit the roof of CDC’s respiratory illness level scale</strong> - Uptake of flu shots is lagging this year, CDC says. - <a href="https://arstechnica.com/?p=1897339">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>LockBit ransomware suspect nabbed in Canada, faces charges in the US</strong> - Automation features make LockBit one of the more destructive pieces of ransomware. - <a href="https://arstechnica.com/?p=1897321">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Control, one of ray tracing’s first killer apps, is getting a sequel</strong> - One of PC gaming’s proudest new franchises is going big. - <a href="https://arstechnica.com/?p=1897331">link</a></p></li>
</ul>
<h1 data-aos="fade-right" id="from-jokes-subreddit">From Jokes Subreddit</h1>
<ul>
<li><strong>What’s the difference between grey and gray?</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
One is a color, and the other is a colour.
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/Kyle______"> /u/Kyle______ </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/yshook/whats_the_difference_between_grey_and_gray/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/yshook/whats_the_difference_between_grey_and_gray/">[comments]</a></span></p></li>
<li><strong>Why did the US take the “u” out of words like “colour” and “honour”?</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Because, fuck you, that’s why
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/AMAZING_PUDDING"> /u/AMAZING_PUDDING </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/ysuof8/why_did_the_us_take_the_u_out_of_words_like/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/ysuof8/why_did_the_us_take_the_u_out_of_words_like/">[comments]</a></span></p></li>
<li><strong>Three soviet factory workers were recently arrested…</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
1 came into work too early and was tried for espionage.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
1 came into work too late and was tried for sabotage.
</p>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
And 1 came in on time, meaning he had an illegally imported western watch.
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/Rocketman7158"> /u/Rocketman7158 </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/ys7wm2/three_soviet_factory_workers_were_recently/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/ys7wm2/three_soviet_factory_workers_were_recently/">[comments]</a></span></p></li>
<li><strong>My 60+ year-old coworker is very proud of this joke she came up with: How many lesbians does it take to change a lightbulb?</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Only two, but they do it lickety-split
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/LoudLalochezia"> /u/LoudLalochezia </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/yssslv/my_60_yearold_coworker_is_very_proud_of_this_joke/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/yssslv/my_60_yearold_coworker_is_very_proud_of_this_joke/">[comments]</a></span></p></li>
<li><strong>…and the bartender said: “we don’t serve hypothetical faster-than-light particles here!”</strong> - <!-- SC_OFF -->
<div class="md">
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
A tachyon walks into a bar…
</p>
</div>
<!-- SC_ON -->
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/Mach10vector"> /u/Mach10vector </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/yspbvc/and_the_bartender_said_we_dont_serve_hypothetical/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/yspbvc/and_the_bartender_said_we_dont_serve_hypothetical/">[comments]</a></span></p></li>
</ul>
<script>AOS.init();</script></body></html>

4
index.html
View File

File diff suppressed because one or more lines are too long